Suchergebnisse - "Nikanjam, Mina"

PubPharm (83)

51

Population pharmacokinetics of siltuximab: impact of disease state

enthalten in: Cancer chemotherapy and pharmacology | 2019

von Nikanjam, M. | Yang, J. | Capparelli, E.

52

Population pharmacokinetics of siltuximab: impact of disease state

enthalten in: Cancer chemotherapy and pharmacology | 2019

von Nikanjam, M. | Yang, J. | Capparelli, E.

53

Population pharmacokinetics of siltuximab: impact of disease state

enthalten in: Cancer chemotherapy and pharmacology | 2019

von Nikanjam, M. | Yang, J. | Capparelli, E.

54

Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults

enthalten in: Therapeutic drug monitoring | 2018

von Lin, S. | Nikanjam, M. | Capparelli, E. | +10

ErratumIn: Ther Drug Monit. 2019 Apr;41(2):256. - PMID 30883523

55

Population Pharmacokinetics of Lopinavir/Ritonavir : Changes Across Formulations and Human Development From Infancy Through Adulthood

enthalten in: Journal of clinical pharmacology | 2018

von Yang, J. | Nikanjam, M. | Best, B. | +6

56

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction : The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience

enthalten in: Cureus | 2018

von Nikanjam, M. | Wing, J. | Capparelli, E. | +1

57

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

enthalten in: Journal of clinical pharmacology | 2018

von Yang, J. | Patel, M. | Nikanjam, M. | +8

58

Vincristine-associated Neuropathy With Antifungal Usage : A Kaiser Northern California Experience

enthalten in: Journal of pediatric hematology/oncology | 2018

von Nikanjam, M. | Sun, A. | Albers, M. | +5

59

Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351 : population pharmacokinetic assessment

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Nikanjam, M. | Capparelli, E. | Lancet, J. | +2

60

Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Nikanjam, M. | Capparelli, E. | Lancet, J. | +2